61,600 Shares in OPKO Health, Inc. (NASDAQ:OPK) Acquired by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd bought a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 61,600 shares of the biotechnology company’s stock, valued at approximately $91,000.

A number of other large investors have also recently added to or reduced their stakes in OPK. Rubric Capital Management LP boosted its holdings in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Clearline Capital LP bought a new stake in OPKO Health during the third quarter worth approximately $1,083,000. Essential Planning LLC. bought a new stake in OPKO Health during the fourth quarter worth approximately $506,000. Barclays PLC boosted its holdings in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on OPK shares. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, March 12th.

OPKO Health Trading Up 1.2 %

OPKO Health stock opened at $1.74 on Monday. OPKO Health, Inc. has a 52 week low of $0.86 and a 52 week high of $2.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.16 and a beta of 1.70. The company has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.57.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. Research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 67,434 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were acquired at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the acquisition, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders purchased a total of 764,971 shares of company stock worth $1,145,692 in the last quarter. 47.26% of the stock is currently owned by corporate insiders.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.